Taurine in Peripartum Cardiomyopathy

Phase 3CompletedNCT03907267

Ain Shams University40 enrolled

Overview

Taurine as an adjunct for early left ventricular recovery in peripartum cardiomyopathy

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Peripartum Cardiomyopathy

Interventions

Taurine SolutionDRUG

Taurine Solution

Normal SalineDIETARY_SUPPLEMENT

Normal Saline

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Peripartum Cardiomyopathy Exclusion Criteria: * Other identifiable cause for heart failure * low LVEF ≤ 25% * sepsis * autoimmune disease * severe chronic disease * malignancy

Locations (1)

Ain Shams University Maternity Hospital

Cairo, Egypt

Outcomes

Primary Outcomes

improvement of the left ventricular ejection fraction >10 %

improvement of the left ventricular ejection fraction \>10 %

Time frame: 1 week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.